2 results
Approved WMOWill not start
To evaluate the long-term safety and tolerability of elsubrutinib and upadacitinib given alone or as the ABBV-599 (elsubrutinib/upadacitinib) combination in SLE subjects who have completed the M19-130 Phase 2 study.
Approved WMORecruiting
The main objective of this dose-finding study is to evaluate the analgesic effect of STR-324 (maximum 4 increasing doses and maximum 2-hours infusion) on post-operative pain, measured by change of pain intensity assessed on a Numerical Rating Scaleā¦